Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03251027 · ClinicalTrials.gov registry record · NA

Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma

A NA study of Glioblastoma and WHO Grade III Glioma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.

Active
Registry status
NA
Development phase
100
Enrollment target
1
Study location

NCT03251027 is a NA study of Glioblastoma and WHO Grade III Glioma that is active but no longer recruiting, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 100 participants, roughly in line with the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03251027, a NA study of Glioblastoma and WHO Grade III Glioma, is active but no longer recruiting, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
100 participants
Enrollment target
1
Study location

Study Summary

This phase II trial studies how well intensity-modulated stereotactic radiation therapy works in treating patients with grade II-IV glioma. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to normal tissue.

Interventions

  • RADIATION Intensity-Modulated Radiation Therapy
  • OTHER Quality-of-Life

Study Locations (1)

Pennsylvania

  • Sidney Kimmel Cancer Center at Thomas Jefferson University - Philadelphia

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2017-07-17
Est. Completion 2027-12-31
Phase NA

What the Registry Record Tells You About NCT03251027

The ClinicalTrials.gov registry entry for NCT03251027 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 108-participant average among 199 other Glioblastoma trials with a reported enrollment target. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Glioblastoma appearing as the primary indexed condition, and to 2 interventions - of which Intensity-Modulated Radiation Therapy is the first listed.

NCT03251027 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT03251027 about?

NCT03251027 is a clinical study titled "Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma". This phase II trial studies how well intensity-modulated stereotactic radiation therapy works in treating patients with grade II-IV glioma. Stereotactic radiosurgery is a specialized radiation therapy that delivers a single, high dose of radiation directly to the tumor and may cause less damage to n...

What is the current status of trial NCT03251027?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 100 participants. The study started on 2017-07-17. Estimated completion is 2027-12-31.

What conditions does trial NCT03251027 study?

This clinical trial studies the following conditions: Glioblastoma, WHO Grade III Glioma, WHO Grade II Glioma.

What interventions are being tested in trial NCT03251027?

The interventions under investigation include: Intensity-Modulated Radiation Therapy (RADIATION), Quality-of-Life (OTHER).

Who is sponsoring clinical trial NCT03251027?

This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03251027 being conducted?

This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Glioblastoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.